A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.

Nat Commun · 2024 · PMC10902357 · PMID 38418463

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendP = 0.08so close (0.05 < p ≤ 0.1)

5a ), and these participants also showed a trend towards shorter OS (median 15 versus 28 months; HR 2.0, 95% CI 0.88–4.64, P = 0.08) (Supplementary Fig. 5b ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.